Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Core Insights - The article highlights that 95% of patients reported being very satisfied or satisfied with thermal ablation procedures, indicating a high level of patient satisfaction with this treatment option [1] - Cryoablation using ProSense® demonstrated the highest complete ablation rate compared to alternative methods, with no reported adverse events, showcasing its effectiveness and safety [1] Company and Industry Summary - IceCure Medical Ltd. is associated with advancements in thermal ablation and cryoablation technologies, contributing to improved cosmetic outcomes and patient satisfaction in surgical oncology [1] - The findings from the European Journal of Surgical Oncology and Radiology publications reinforce the growing acceptance and preference for minimally invasive ablation techniques in the medical field [1]